跳至主要内容
临床试验/RBR-72tgny
RBR-72tgny招募中1 期

Assessment of Primary Dermal Irritability, Dermal Irritability and Dermal Sensitization (HRIPT).

Medcin Instituto da Pele Ltda.0 个研究点开始时间: 2019年6月7日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 70Y(—)

入选标准

  • Age between 18 and 70 years; Phototypes I, II, III and IV as adapted Fitzpatrick scale Annex 1; Skin of the whole test region;

排除标准

  • Gestation or risk of gestation and / or lactation when women; Use of anti-inflammatory drugs 30 days and / or immunosuppressants for up to three months prior to selection; Immunosuppression by drugs or active diseases;
  • Decompensated endocrinopathies; Personal history of atopy; Intense sun exposure or tanning sessions up to 15 days prior to evaluation or during the study period; Forecast of sea baths, swimming pool or sauna during the study; Practice water sports during the study; Dermographism; Use of oral or topical treatment with vitamin A acid and / or its derivatives up to 1 month before the start of the study; Aesthetic and / or dermatological treatment in the body within 03 weeks prior to selection; Scheduled vaccination during the study period or until 03 weeks prior to screening; History of sensitization and irritation to topical product; Active skin conditions (local and / or disseminated) that may interfere with the results of the study; Use of new drugs and / or cosmetics during the study; Skin reactivity; Previous participation in studies with the same product; Congenital or acquired immunodeficiency; Relevant clinical history or current evidence of alcohol or other drug abuse; Known or suspected intolerance of any ingredient in the study products test or comparative products; History of lack of adherence or unwillingness to adhere to the study protocol; Employees of Medcin or the sponsoring company involved in the study, or a close family member of an employee involved in the study. Other conditions considered by the researcher as reasonable for disqualification of study participation. If Yes, it should be described in observation in the clinical file;

研究者

相似试验